MedPath

Clinical Feasibility of a New Voice Prosthesis

Not Applicable
Completed
Conditions
Laryngectomy
Interventions
Device: New Voice Prosthesis
Registration Number
NCT05079386
Lead Sponsor
Atos Medical AB
Brief Summary

The objective of this clinical investigation is to evaluate the short-term clinical feasibility of a new voice prosthesis and explore its acceptability, limitations and advantages. As a result of the evaluations, design changes may be implemented and evaluated until the optimal design has been determined, or until it is decided not to pursue further development of the device. Main outcome will be the patient's acceptance of the voice prosthesis, secondary outcomes are stickiness of the valve mechanism and speech.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
17
Inclusion Criteria
  • Laryngectomized patients using either the Provox Vega 22.5 or the Provox ActiValve Light voice prosthesis, with a length of 4, 6, 8, or 10 mm
  • 18 years and older
Exclusion Criteria
  • Current tracheoesophageal puncture problems such as enlarged puncture or infection
  • Active recurrent or metastatic disease (medical deterioration)
  • The use of ActiValve Strong/XtraStrong or XtraSeal
  • Unable to understand the Patient Information and/or unable to give Informed Consent
  • The previous 2 VPs had a device lifetime > 12 months
  • History of oral resections negatively affecting speech

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
New Voice ProsthesisNew Voice ProsthesisPatients will use the New Voice Prosthesis for two weeks to investigate short term feasibility and explore limitations and advantages. If the patient wishes to leave the New Voice Prosthesis in situ, this will be allowed under the condition that the subject agrees to remain in the study and report (adverse) events on an ongoing basis, until the device is removed after a maximum of 12 months.
Primary Outcome Measures
NameTimeMethod
Patient acceptability2 week

Patient recorded acceptability of the voice prosthesis based on study specific questionnaires covering: 1) Experienced stickiness, 2) Effort to speak and 3) maintenance of voice prosthesis. Assessed by Yes/No and multiple choice questions.

Secondary Outcome Measures
NameTimeMethod
Voice Handicap Index - 10Baseline and 2 weeks

Validated tool to assess Voice handicap. Statements on participant's voice quality and effect on social life are assessed by a five-point Likert-scale, ranged from 0-4, with high scores indicating more handicap (0 = Never, 4 = Always).

Voice Assessment - Maximum phonationBaseline and 2 weeks

Longest maximum phonation time in seconds out of 2 consecutive attempts. Assessed with current Voice prosthesis and the New Voice Prosthesis.

Voice Assessment - Highest volumeBaseline and 2 weeks

Highest volume in hertz. Assessed with current Voice prosthesis and the New Voice Prosthesis.

Voice Assessment - Lowest VolumeBaseline and 2 weeks

Lowest volume in hertz. Assessed with current Voice prosthesis and the New Voice Prosthesis.

Quality of Life by EQ-5D-5LBaseline and 2 weeks

Patient reported, the descriptive system assesses health in five dimensions, from which a health state index score is calculated, range from 0 to 1, with higher scores indicating higher health utility

Voice Assessment - Glide tonesBaseline and 2 weeks

Successful completion of glide town, from low to high. Assessed with current Voice Prosthesis and the New Voice Prosthesis.

Device lifeBaseline, and week 52

Device life of two previous Voice prosthesis and device life of the New Voice Prosthesis in the long-term part of study.

Voice Assessment - SoftnessBaseline and 2 weeks

Speaking as soft as possible in decibels. Assessed with current Voice prosthesis and the New Voice Prosthesis.

Voice Assessment - LoudnessBaseline and 2 weeks

Speaking as loud as possible in decibels. Assessed with current Voice prosthesis and the New Voice Prosthesis.

Trial Locations

Locations (1)

Netherlands Cancer Institute: NKI

🇳🇱

Amsterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath